Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Johnson & Johnson is celebrating after advisors to the US Food and Drug Administration recommended approval for the diabetes treatment canagliflozin, despite safety concerns.
The agency's Endocrinologic and Metabolic Drugs Advisory Committee voted 10-5 in support of canagliflozin. If approved, the selective sodium glucose co-transporter 2 (SGLT2) inhibitor will be the first in that class to get the thumbs-up in the USA and it will be sold as Invokana.
http://www.pharmatimes.com/Article/...J_J_diabetes_drug_despite_heart_concerns.aspx
The agency's Endocrinologic and Metabolic Drugs Advisory Committee voted 10-5 in support of canagliflozin. If approved, the selective sodium glucose co-transporter 2 (SGLT2) inhibitor will be the first in that class to get the thumbs-up in the USA and it will be sold as Invokana.
http://www.pharmatimes.com/Article/...J_J_diabetes_drug_despite_heart_concerns.aspx